Physician profile
Mary E Tullos
NPI 1639339682
$5,949.60
in general payments reported to CMS, 2019-2025
33 companies · $867 in 2025
The $867 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,558 · 2022: $1,393 · 2023: $1,110 · 2024: $1,021 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938 · Education: $60.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,938.21 |
| Education | $60.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $963.75 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $745.82 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $697.42 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $502.58 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $393.45 | 2021-2025 | |
| Amarin Pharma, INC. | $328.11 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.96 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $253.37 | 2021-2025 | Belsomra, Capvaxive, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $216.26 | 2022 | |
| Sanofi-Aventis U.S. LLC | $198.57 | 2021-2023 | |
| Abbott Laboratories | $188.76 | 2021-2024 | Freestyle Libre, Freestyle Libre 3 |
| Pfizer INC. | $153.75 | 2021-2024 | |
| Eisai INC. | $107.59 | 2021 | |
| Amgen INC. | $107.48 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $90.38 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $75.30 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $73.58 | 2023-2025 | Veozah |
| Boston Scientific Corporation | $68.91 | 2025 | Cds - Mct/Cem Monitoring, Watchman Flx |
| Janssen Pharmaceuticals, INC | $60.43 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $60.41 | 2024 | Tryvio |
| Shield Therapeutics INC | $59.64 | 2023-2025 | Accrufer |
| Phathom Pharmaceuticals, INC. | $58.97 | 2024-2025 | Voquezna |
| Dexcom, INC. | $57.62 | 2021-2025 | Dexcom G6 Transmitter |
| Electromed, INC. | $37.07 | 2025 | Smartvest |
| Exact Sciences Corporation | $27.74 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $26.62 | 2021-2022 | |
| Edwards Lifesciences Corporation | $24.47 | 2025 | Sapien 3 Ultra Resilia |
| Axsome Therapeutics, INC. | $21.22 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $18.87 | 2024 | Trintellix |
| Esperion Therapeutics, INC. | $17.09 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.15 | 2021 | |
| Endo Pharmaceuticals INC. | $14.03 | 2021 | |
| Hikma Pharmaceuticals USA | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Tullos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.